|
Match
|
Document |
Document Title |
|
|
US20140105886 |
ASSOCIATION OF BIOMARKERS WITH PATIENT OUTCOME
Glioblastoma multiforme (GBM) is an aggressive form of brain cancer. Biomarkers for GBM that provide prognostic and predictive information are useful because they provide the physician valuable... |
|
|
US20150079116 |
DIAGNOSTIC TOOLS FOR RESPONSE TO 6-THIOPURINE THERAPY
NK cell licensing predisposes patients to chronic inflammatory disease. Methods and kits to diagnose and treat chronic inflammatory disease based on genetic haplotype and cytokine profile are... |
|
|
US20150250770 |
LKB1 AS PREDICTIVE MARKER OF EVEROLIMUS EFFICACY IN BREAST CANCER
Method for identifying a breast cancer likely to respond to treatment with everolimus comprising the following steps: Measuring the level of expression of the LKB 1 gene in a breast tumour sample... |
|
|
US20130018069 |
SUSTAINED RELEASE DELIVERY SYSTEMS FOR THE PREVENTION AND TREATMENT OF HEAD AND NECK CANCERS
The present invention discloses a method of treating a head and neck cancer or preventing the development of pre-malignant lesions to this cancer, by administering locally to the oral cavity, a... |
|
|
US20110224245 |
Treatment Of Neurological Disorders Using Huperzine
Methods and compositions containing huperzine for direct delivery to central nervous system (CNS) tissue are used to alleviate pain and for the prevention and/or treatment of seizures and... |
|
|
US20140056999 |
TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM
The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible... |
|
|
US20110117213 |
TREATMENT OF ACUTE EXACERBATION OF ASTHMA AND REDUCTION OF LIKELIHOOD OF HOSPITALIZATION OF PATIENTS SUFFERING THEREFROM
The invention provides a method of improving one or more clinical outcomes of an individual experiencing an acute respiratory attack. The acute respiratory attack may include acute reversible... |
|
|
US20140336215 |
Rhinitis Treatment Regimens
A method of treating rhinitis and rhinorrhea includes taking a daytime oral dosage unit containing a non-sedating antihistamine for treating rhinitis and an anticholinergic agent having limited... |
|
|
US20110086081 |
COATING SYSTEM AND METHOD FOR DRUG ELUTION MANAGEMENT
The teachings are directed to a medical device having a drug-retaining coating that at least substantially delays the initial elution of a drug for a time effective at forming a functional... |
|
|
US20130022661 |
BIO-REMODABLE BONE AUGMENTATION DEVICE AND METHOD
A bio-remodable augmentation device including an implantable member configured for maintaining space in a bone defect. The implantable member is formed from a bio-remodable composite having... |
|
|
US20110150775 |
GENOMIC APPROACHES TO FETAL TREATMENT AND DIAGNOSIS
The present invention provides systems for developing and/or testing therapies for prenatal diseases and conditions including Down Syndrome. The present invention also provides diagnostic methods... |
|
|
US20150004154 |
REGIMEN FOR SUPPRESSING ORGAN REJECTION
The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus... |
|
|
US20110104228 |
SELF-ELIMINATING COATINGS
The invention features the use of a matrix consisting of low molecular weight components for use as a self-eliminating coating for implantable medical devices. The matrix coatings can be used to... |
|
|
US20110045050 |
NANOEMULSION FORMULATIONS FOR DIRECT DELIVERY
A nanoemulsion and corresponding methods of making and using systems of single or blended high HLB value surfactant(s) for the emulsification of single or blended oils and vitamin E components in... |
|
|
US20130017257 |
DRY POWDER FORMULATION CONTAINING TIOTROPIUM FOR INHALATION
The present invention is related to a dry powder formulation containing tiotropium to be administered via inhalation, the use of said formulation in the treatment of respiratory diseases... |
|
|
US20120136046 |
METHOD OF TREATING AGE RELATED DISORDERS
The present invention relates to the use of fujimycin for the treatment of a disorder related to the chronological and/or replicative life-span of a cell, and to methods for increasing the... |
|
|
US20120076770 |
Modulation of autophagy and and serotonin for treatment of multiple myeloma related diseases
THE INVENTION RELATES TO compounds, proteins and methods of treatment therewith. Aspects of embodiments of the invention further relates to compounds and methods of treatment for bone, bone... |
|
|
US20140080834 |
INHIBITION OF ADAPTOR ASSOCIATED KINASE 1 FOR THE TREATMENT OF PAIN
This invention is directed to the treatment of pain by inhibiting adaptor associated kinase 1 (AAK1). Numerous AAK1 inhibitors are disclosed. |
|
|
US20130213398 |
DRY POWDER FORMULATIONS AND METHODS FOR TREATING PULMONARY DISEASES
The present invention is directed toward respirable dry particles for delivery of divalent metal cation salts and/or monovalent cation salts to the respiratory tract and methods for treating a... |
|
|
US20130231346 |
METHODS OF TREATING CANCER
Methods for treating a human with cancer comprise administering a therapeutically effective amount of at least one MEK inhibitor and at least one mTOR inhibitor to said patient, wherein said... |
|
|
US20150133378 |
METHOD FOR PREDICTING RISK OF EXPOSURE TO INTERSTITIAL FIBROSIS AND TUBULAR ATROPHY WITH CLUSTERIN
A method for identifying a kidney transplant recipient at an increased risk of developing interstitial fibrosis or tubular atrophy which comprises obtaining a post-transplant urine sample from the... |
|
|
US20100322894 |
Combination Therapies for Treating Type 1 Diabetes
In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes. |
|
|
US20110028418 |
USE OF GABBA RECEPTOR ANTAGONISTS FOR THE TREATMENT OF EXCESSIVE SLEEPINESS AND DISORDERS ASSOCIATED WITH EXCESSIVE SLEEPINESS
GABAA receptor mediated hypersomnia can be treated by administering a GABAA receptor antagonist (e.g., flumazenil; clarithromycin; picrotoxin; bicuculline; cicutoxin; and oenanthotoxin). In some... |
|
|
US20140024642 |
OPHTHALMIC FORMULATION AND METHOD FOR AMELIORATING PRESBYOPIA
An ophthalmic formulation having an effective amount of a parasympathomimetic agent comprising pilocarpine, or a pharmaceutically acceptable salt thereof, and one or more α1 adrenergic agonists or... |
|
|
US20120015035 |
Implantable Delivery Vehicle for Ocular Delivery of Muscarinic Antagonists
The present invention provides compositions and methods for treating ocular disorders such as myopia. |
|
|
US20120059027 |
TACROLIMUS INJECTION PREPARATION
A tacrolimus injection preparation comprising tacrolimus, polyoxyethylene castor oil (35), and non-aqueous solvent is disclosed. Preferably the weight ratio of polyoxyethylene castor oil (35) to... |
|
|
US20140194461 |
RAPAMYCIN FORMULATIONS AND METHODS OF THEIR USE
Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and... |
|
|
US20110165256 |
COMPOSITIONS AND METHODS FOR TREATMENT OF HYPERPLASIA
In accordance with the present invention, there are provided methods for treating hyperplasia in a subject in need thereof. In another aspect of the invention, there are provided methods for... |
|
|
US20140080783 |
PHARMACEUTICAL COMBINATIONS FOR TREATMENT OF SPECIFIC CANCERS
The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer,... |
|
|
US20120071435 |
PHARMACEUTICAL COMBINATIONS COMPRISING FOR THE TREATMENT OF SPECIFIC CANCERS
The present invention relates to the field of oncology and provides compositions and methods for treating specific cancers, including non small cell lung cancer, breast cancer, thyroid cancer,... |
|
|
US20110311605 |
Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings
Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same. |
|
|
US20110251677 |
Coating Designs For The Tailored Release Of Dual Drugs From Polymeric Coatings
Provided herein are coating designs for the tailored release of two therapeutic agents from polymer coatings and methods of making and using the same. |
|
|
US20140378500 |
METHODS FOR PREDICTING TUMOR REPONSE TO TARGETED THERAPIES
A method for identifying cancer patients that are likely to be responders or non-responders to a signal transduction pathway inhibitor is described. |
|
|
US20140303091 |
OCULAR FORMULATIONS OF NORKETOTIFEN
Ophthalmic compositions containing norketotifen and methods of making the same and the use thereof are disclosed. The methods also comprise administering to the eyes of a mammal in need thereof... |
|
|
US20130261148 |
PROTECTED ANTIMICROBIAL COMPOUNDS FOR HIGH TEMPERATURE APPLICATIONS
Provided are protected antimicrobial compounds which are useful for controlling microorganisms in aqueous or water-containing systems, such as oil or gas field fluids, at elevated temperature. The... |
|
|
US20140370072 |
PROHEALING PIEZOELECTRIC COATINGS
Provided herein is a prohealing piezoelectric coating and the method of making and using the same. |
|
|
US20120329759 |
FORMULATIONS AND METHODS FOR VASCULAR PERMEABILITY-RELATED DISEASES OR CONDITIONS
Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability. |
|
|
US20110224128 |
METHODS AND COMPOSITIONS FOR TREATMENT OF MUSCULAR DYSTROPHY
The invention features methods, compositions, and kits useful for the treatment of muscular dystrophy, e.g., Duchenne muscular dystrophy, in a patient. |
|
|
US20110311629 |
NON-ADHESIVE ELASTIC GELATIN MATRICES
The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix... |
|
|
US20110097402 |
NON-ADHESIVE ELASTIC GELATIN MATRICES
The present invention is a substantially non-adhesive elastic gelatin matrix. The matrix is both non-adhesive to wounds, tissues and organs and is also elastic such that it is flexible. The matrix... |
|
|
US20140356407 |
BIODEGRADABLE SUPPORTING DEVICE
A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of... |
|
|
US20130236498 |
BIODEGRADABLE SUPPORTING DEVICE
A biodegradable in vivo supporting device is disclosed. The in vivo supporting device comprises a biodegradable metal scaffold and a biodegradable polymer coating covering at least a portion of... |
|
|
US20140303201 |
CANCER THERAPY
The subject invention provides for cancer therapy. |
|
|
US20090060922 |
Acetamide Stereoisomer
The compound of formula (I) is a water-stable, long acting β2-selective adrenoceptor agonist useful as a bronchodilator in the treatment of bronchoconstriction associated with reversible... |
|
|
US20110301105 |
COMPOSITIONS FOR PROLIFERATION OF CELLS AND RELATED METHODS
We have discovered that p63 inhibition results in increased cellular proliferation. We have also performed a screen for agents capable of increasing cellular proliferation, (e.g., of stem cells... |
|
|
US20110118298 |
COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF CANCER
Described herein are compositions, kits, and methods for determining whether subjects having cancer(s) are likely to respond to treatment with an HSP90 inhibitor, as a single agent or in... |
|
|
US20140357660 |
GENE EXPRESSION SIGNATURES OF NEOPLASM RESPONSIVENESS TO THERAPY
Gene signatures for determining whether a neoplasm (such as a multiple myeloma neoplasm) is sensitive to mTORi/HDACi combination therapy and/or for determining the prognosis of a neoplasm in a... |
|
|
US20140011834 |
STABLE FORMULATIONS, AND METHODS OF THEIR PREPARATION AND USE
Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of... |
|
|
US20110118297 |
Tivozanib and Temsirolimus in Combination
A method of treating a tumor in a human patient is disclosed. The method comprises co-administering to the patient: (a) a dose of 1.5 mg tivozanib per day; and (b) a dose of 25 mg temsirolimus per... |
|
|
US20130225631 |
TOPICAL RAPAMYCIN FOR TREATMENT OF FACIAL ANGIOFIBROMAS IN TUBEROUS SCLEROSIS
The present disclosure provides for a method and a topical composition to treat facial angiofibromas in Tuberous Sclerosis by applying from about 0.25% to about 2% rapamycin to a small body... |